Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 22, 2011
Event: Entry into a Material Definitive Agreement regarding the appointment of a new Chairman of the Scientific Advisory Board.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a corporate governance appointment.
Material Changes
Appointment: Dr. Michael Berelowitz, M.D., has been appointed as the Chairman of the Scientific Advisory Board.
Role Responsibilities: Active involvement in scientific decisions, clinical strategy, and partnership negotiations.
Compensation Structure:
- Hourly Rate: $300 per hour.
- Daily Cap: Up to $1,500 per day.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The appointment is intended to strengthen the company's scientific and strategic direction.
Investor Verification Checklist
- Verify the terms of the agreement attached as Exhibit 99.2 for any additional compensation clauses or termination conditions not summarized in the 8-K.
- Review the attached press release (Exhibit 99.1) for further details on Dr. Berelowitz's background and specific strategic goals.
- Check subsequent filings for the actual utilization of the daily compensation cap and the duration of the engagement.